Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in choroid plexus epithelial cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3914
Sealed predictions
- SYNGAP1 in dopamine neurons, braak-0.67 (p 0.047) → -0.44 (p 0.240)receipt 3922
Swarm cases
receipt 3922: SYNGAP1 in dopamine neurons, braak
- power
- full sample -0.54 (p 0.021, n 18), 95% CI -0.80 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.53 (p 0.024, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.69 (p 0.0015, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.48, sign flips 0; without severely affected donors -0.54 (p 0.021, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.74 (p 5.0e-4, n 18) vs -0.54 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SYNGAP1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SYNGAP1 · oligodendrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts